<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079854</url>
  </required_header>
  <id_info>
    <org_study_id>TOP_VIGAMOX</org_study_id>
    <nct_id>NCT05079854</nct_id>
  </id_info>
  <brief_title>Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis</brief_title>
  <official_title>Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endophthalmitis is a severe inflammatory eye condition with profound impairment of vision,&#xD;
      which can lead to irreversible visual loss and requires immediate treatment.&#xD;
&#xD;
      There is no way to completely prevent endophthalmitis, however, through prophylactic methods,&#xD;
      it is possible to reduce its incidence. Currently, the only technique that has reached&#xD;
      category II of evidence in reducing the risks of endophthalmitis is the use of 5%&#xD;
      povidone-iodine eye drops, moments before surgery. In 2007, the European Society of Cataract&#xD;
      and Refractive Surgery (ESCRS) released a large multicenter randomized clinical trial, with&#xD;
      data on the reduction in the rates of endophthalmitis, using the intracameral antibiotic&#xD;
      therapy technique of perioperative cefuroxime. However, much is discussed about the risks&#xD;
      related to the technique, such as dilutional errors, contamination, anaphylaxis and&#xD;
      cost-effectiveness, which still makes the conduct debatable.&#xD;
&#xD;
      The study evaluates the use of intracameral Moxifloxacin 0.5% (Vigamox®) as prophylaxis in&#xD;
      cases of endophthalmitis after open ocular trauma;&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endophthalmitis</measure>
    <time_frame>90 days</time_frame>
    <description>Evaluate the incidence of Endophthalmitis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endophthalmitis</condition>
  <condition>Trauma, Corneal</condition>
  <arm_group>
    <arm_group_label>INTRACAMERAL MOXIFLOXACIN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the surgery, the antibiotic is intracameral administered, Moxifloxacin 0.5% 0.1mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOPICAL MOXIFLOXACIN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the surgery, the antibiotic is topical administered, Moxifloxacin 0.5% 0.1mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraocular Instillation Solution</intervention_name>
    <description>Intracameral Moxifloxacin 0.5%</description>
    <arm_group_label>INTRACAMERAL MOXIFLOXACIN</arm_group_label>
    <other_name>Intracameral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Ophthalmic</intervention_name>
    <description>Topical Moxifloxacin 0.5%</description>
    <arm_group_label>TOPICAL MOXIFLOXACIN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  open globe trauma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  endophthalmitis at the beginning&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept of Ophthalmology - UNIFESP/Hospital São Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinicius Campos Bergamo, MD</last_name>
      <phone>(11) 9 80589798</phone>
      <email>viniciusbergamo.epm@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mauricio Maia, MD, PhD</last_name>
      <phone>5511-5572-6443</phone>
      <email>maiamauricio@terra.com.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 3, 2021</study_first_submitted>
  <study_first_submitted_qc>October 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Mauricio Maia</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endophthalmitis</mesh_term>
    <mesh_term>Corneal Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

